Canadian Patents Database

Claims page

---

Patent Document Number: 2699087

(54) English Title: USE OF A PEPTIDE AS A THERAPEUTIC AGENT

(54) French Title: UTILISATION D'UN PEPTIDE EN TANT QU'AGENT THERAPEUTIQUE

---

Claims:

Note: Claims are shown in the official language in which they were submitted.



98

Claims


1. Peptide having the formula Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-
Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-I le-Asn-Met-
Leu-Thr-Arg-Pro-Arg-Tyr-NH2 for use in medicine.


2. Use of the peptide Ala-Pro-Leu-Glu-Pro-Val-Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-
Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-Arg-Tyr-I le-Asn-Met-Leu-Thr-
Arg-Pro-Arg-Tyr-NHZ for the manufacture of a pharmaceutical composition for
treatment and/or prophylaxis of cancer, autoimmune diseases, fibrotic
diseases,
inflammatory diseases, neurodegenerative diseases, infectious diseases, lung
diseases, heart and vascular diseases and metabolic diseases.


3. Use of the peptide according to claim 2, wherein cancer, the autoimmune
disease, fibrotic disease, inflammatory disease, neurodegenerative disease,
infectious disease, lung disease, heart and vascular disease or metabolic
disease is selected from AIDS, AIDS related diseases, HIV, asthma, Omenn's
syndrome, idiopathic pulmonary fibrosis, and atopic disorders in genetically
susceptible individuals.


4. Use of the peptide according to claim 1 for the preparation of a
formulation for
oral administration to newborns, toddlers, and/or infants.


5. Use of the peptide according to claim 1 for the preparation of a
lyophilized
formulation or a buffered liquide formulation.


6. Pharmaceutical composition containing the peptide Ala-Pro-Leu-Glu-Pro-Val-
Tyr-Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-
Arg-Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NHz together with at least one

pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient
and/or diluent.


7. Pharmaceutical composition according to claim 6 in the form of a
lyophilisate or
liquid buffer solution.


8. Pharmaceutical composition according to claim 6 or 7 suitable for
intravenous
administration, oral administration, or for administration by inhalation.



99

9. Pharmaceutical composition according to claim 6, 7 or 8 in the form of an
artificial mother milk formulation or mother milk substitute suitable for oral

delivery to newborns, toddlers and infants.


10. Pharmaceutical composition according to claim 6, 7, 8 or 9 suitable for
the
treatment and/or prophylaxis of cancer, an autoimmune disease, a fibrotic
disease, an inflammatory disease, a neurodegenerative disease, an infectious
disease, a lung disease, a heart and vascular disease or a metabolic disease.


11. Method for treating cancer, an autoimmune disease, a fibrotic disease, an
inflammatory disease, a neurodegenerative disease, an infectious disease, a
lung disease, a heart and vascular disease or a metabolic disease in a mammal,

including a human, which comprises administering to the mammal a
pharmaceutically effective amount of the peptides Ala-Pro-Leu-Glu-Pro-Val-Tyr-
Pro-Gly-Asp-Asn-Ala-Thr-Pro-Glu-Gln-Met-Ala-Gln-Tyr-Ala-Ala-Asp-Leu-Arg-
Arg-Tyr-Ile-Asn-Met-Leu-Thr-Arg-Pro-Arg-Tyr-NH2 or salts and hydrates thereof
effective to treat the cancer, the autoimmune disease, the fibrotic disease,
the
inflammatory disease, the neurodegenerative disease, the infectious disease,
the lung disease, the heart and vascular disease or the metabolic disease.


12. Method according to claim 11, wherein cancer, the autoimmune disease,
fibrotic
disease, inflammatory disease, neurodegenerative disease, infectious disease,
lung disease, heart and vascular disease or metabolic disease is selected from

AIDS, AIDS related diseases, HIV, asthma, Omenn's syndrome, idiopathic
pulmonary fibrosis, and atopic disorders in genetically susceptible
individuals.